+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pharmaceuticals North America (NAFTA) Industry Guide 2014-2023

  • ID: 4771083
  • Report
  • April 2019
  • Region: North America
  • 86 pages
  • MarketLine
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Pharmaceuticals North America (NAFTA) Industry Guide 2014-2023

Summary

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights
  • The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $437.0 billion in 2018.The Mexico was the fastest growing country, with a CAGR of 4.6% over the 2014-18 period.
  • Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $392.8 billion in 2018. This was followed by Canada and Mexico, with a value of $23.5 and $20.7 billion, respectively.
  • The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $484.7 billion in 2023, followed by Canada and Mexico with expected values of $26.4 and $24.6 billion, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to buy
  • What was the size of the NAFTA pharmaceuticals market by value in 2018?
  • What will be the size of the NAFTA pharmaceuticals market in 2023?
  • What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the NAFTA pharmaceuticals market?
Note: Product cover images may vary from those shown
2 of 2
  • Introduction
  • What is this report about?
  • Who is the target reader?
  • How to use this report
  • Definitions
  • NAFTA Pharmaceuticals
  • Industry Outlook
  • Pharmaceuticals in Canada
  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators
  • Pharmaceuticals in Mexico
  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators
  • Pharmaceuticals in The United States
  • Market Overview
  • Market Data
  • Market Segmentation
  • Market outlook
  • Five forces analysis
  • Macroeconomic indicators
  • Company Profiles
  • Leading Companies
  • Appendix
  • Methodology
List Of Tables
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-23
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-18
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2018-23
Table 4: Canada pharmaceuticals market value: $ billion, 2014-18
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2018
Table 6: Canada pharmaceuticals market share: % share, by value, 2018
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2018-23
Table 8: Canada size of population (million), 2014-18
Table 9: Canada gdp (constant 2005 prices, $ billion), 2014-18
Table 10: Canada gdp (current prices, $ billion), 2014-18
Table 11: Canada inflation, 2014-18
Table 12: Canada consumer price index (absolute), 2014-18
Table 13: Canada exchange rate, 2014-18
Table 14: Mexico pharmaceuticals market value: $ billion, 2014-18
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2018
Table 16: Mexico pharmaceuticals market share: % share, by value, 2018
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2018-23
Table 18: Mexico size of population (million), 2014-18
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2014-18
Table 20: Mexico gdp (current prices, $ billion), 2014-18
Table 21: Mexico inflation, 2014-18
Table 22: Mexico consumer price index (absolute), 2014-18
Table 23: Mexico exchange rate, 2014-18
Table 24: United States pharmaceuticals market value: $ billion, 2014-18
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2018
Table 26: United States pharmaceuticals market share: % share, by value, 2018
Table 27: United States pharmaceuticals market value forecast: $ billion, 2018-23
Table 28: United States size of population (million), 2014-18
Table 29: United States gdp (constant 2005 prices, $ billion), 2014-18
Table 30: United States gdp (current prices, $ billion), 2014-18
Table 31: United States inflation, 2014-18
Table 32: United States consumer price index (absolute), 2014-18
Table 33: United States exchange rate, 2014-18
Table 34: Apotex, Inc.: key facts
Table 35: Johnson & Johnson: key facts
Table 36: Johnson & Johnson: key financials ($)
Table 37: Johnson & Johnson: key financial ratios
Table 38: Bayer AG: key facts
Table 39: Bayer AG: key financials ($)
Table 40: Bayer AG: key financials (€)
Table 41: Bayer AG: key financial ratios
Table 42: Novartis AG: key facts
Table 43: Novartis AG: key financials ($)
Table 44: Novartis AG: key financial ratios
Table 45: AstraZeneca PLC: key facts
Table 46: AstraZeneca PLC: key financials ($)
Table 47: AstraZeneca PLC: key financial ratios
Table 48: Merck & Co., Inc.: key facts
Table 49: Merck & Co., Inc.: key financials ($)
Table 50: Merck & Co., Inc.: key financial ratios
Table 51: Pfizer Inc: key facts
Table 52: Pfizer Inc: key financials ($)
Table 53: Pfizer Inc: key financial ratios

List of Figures
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-23
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-18
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2018-23
Figure 4: Canada pharmaceuticals market value: $ billion, 2014-18
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 6: Canada pharmaceuticals market share: % share, by value, 2018
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2018-23
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2018
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2018
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2018
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2018
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2018
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2018
Figure 14: Mexico pharmaceuticals market value: $ billion, 2014-18
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2018
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2018-23
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2018
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2018
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2018
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2018
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2018
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2018
Figure 24: United States pharmaceuticals market value: $ billion, 2014-18
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 26: United States pharmaceuticals market share: % share, by value, 2018
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2018-23
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2018
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2018
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2018
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2018
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2018
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2018
Figure 34: Johnson & Johnson: revenues & profitability
Figure 35: Johnson & Johnson: assets & liabilities
Figure 36: Bayer AG: revenues & profitability
Figure 37: Bayer AG: assets & liabilities
Figure 38: Novartis AG: revenues & profitability
Figure 39: Novartis AG: assets & liabilities
Figure 40: AstraZeneca PLC: revenues & profitability
Figure 41: AstraZeneca PLC: assets & liabilities
Figure 42: Merck & Co., Inc.: revenues & profitability
Figure 43: Merck & Co., Inc.: assets & liabilities
Figure 44: Pfizer Inc: revenues & profitability
Figure 45: Pfizer Inc: assets & liabilities
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll